Overall survival in the t(4;11)/KMT2A-AFF1 and 14q32/IGH subgroups. (A) Without censoring patients who received allogeneic SCT in first CR. At 5 years, OS was estimated at 45.8% (95% CI, 34-57) in the t(4;11)/KMT2A-AFF1 subgroup and at 30.6% (95% CI, 14-49) in the 14q32/IGH subgroup, in comparison with 63.2% (95% CI, 54-71) in the subgroup with no identified cytogenetic abnormality (HR, 1.17 [95% CI, 1.05-1.30] and 1.13 [95% CI, 1.06-1.21]; P = .005 and <.001, respectively). (B) Censoring patients who received allogeneic SCT in first CR at SCT time. At 5 years, OS was estimated at 27.6% (95% CI, 12-46) in the t(4;11)/KMT2A-AFF1 subgroup and at 20.2% (95% CI, 4-45) in the 14q32/IGH subgroup, in comparison with 65.1% (95% CI, 53-75) in the subgroup with no identified cytogenetic abnormality (HR, 1.32 [95% CI, 1.14-1.53] and 1.16 [95% CI, 1.07-1.26]; P < .001 and <.001, respectively).